首页> Molecular oncology> Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.

Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.

导出 OA

翻译打印收藏纠错

第一作者： Rafal,Dziadziuszko

第一单位： Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland.

作者： Rafal,Dziadziuszko ^[1] ; Tiffany,Hung ^[2] ; Kun,Wang ^[3] ; Voleak,Choeurng ^[4] ; Alexander,Drilon ^[5] ; Robert C,Doebele ^[6] ; Fabrice,Barlesi ^[7] ; Charlie,Wu ^[2] ; Lucas,Dennis ^[8] ; Joel,Skoletsky ^[9] ; Ryan,Woodhouse ^[10] ; Meijuan,Li ^[11] ; Ching-Wei,Chang ^[4] ; Brian,Simmons ^[12] ; Todd,Riehl ^[12] ; Timothy R,Wilson ^[2]

作者单位： Department of Oncology and Radiotherapy, Medical University of Gdańsk, Gdańsk, Poland. ^[1] Oncology Biomarker Department, Genentech, Inc., South San Francisco, CA, USA. ^[2] Biostatistics, Foundation Medicine Inc., Cambridge, MA, USA. ^[3] Oncology Biostatistics, Genentech, Inc., South San Francisco, CA, USA. ^[4] Early Drug Development Service, Memorial Sloan Kettering Cancer Center, and Weill Cornell Medical College, New York, NY, USA. ^[5] Anschutz Medical Campus, University of Colorado, Aurora, CO, USA. ^[6] The National Centre for Scientific Research (CNRS), The National Institute of Health and Medical Research (INSERM), Aix Marseille University, Marseille, France.;Medical Oncology, Gustave Roussy, Villejuif, France. ^[7] Franchise Development, Foundation Medicine Inc., Cambridge, MA, USA. ^[8] Companion Diagnostics Development, Foundation Medicine Inc., Cambridge, MA, USA. ^[9] Regulatory Affairs, Foundation Medicine Inc., Cambridge, MA, USA. ^[10] Biometrics and Biomarkers, Foundation Medicine Inc., Cambridge, MA, USA. ^[11] Product Development Oncology, Genentech, Inc., South San Francisco, CA, USA. ^[12]

关键词 NTRK ROS1 F1L CDx genomic profiling resistance